JL
Insider
Joseph P Lyssikatos
CHIEF SCIENTIFIC OFFICERJoseph P Lyssikatos (CHIEF SCIENTIFIC OFFICER) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $3.5M of ELVN (132,500 sh across 4 lots, as filed), executed Jan 8.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$4.7M
shares × price, as filed
Last traded
Feb 6
Filed Feb 10
Median ADV $83.7M across their filed names
Open performance→Volume by month
Buys $0
Sells $7.5M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
ELVNRecent filings
ELVNSALE
Enliven Therapeutics, Inc.
View filing →
$145K5,000 sh × $29.04
Exec Feb 6
Filed Feb 10 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $535K
20,000 sh across 2 lots
Exec Jan 20
Filed Jan 22 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $3.5M
132,500 sh across 4 lots
Exec Jan 8
Filed Jan 12 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $268K
12,008 sh × $22.30
Exec Nov 19 2025
Filed Nov 21 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $276K
12,500 sh × $22.08
Exec Oct 20 2025
Filed Oct 22 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $150K
7,500 sh × $20.01
Exec Aug 21 2025
Filed Aug 21 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $265K
11,924 sh × $22.26
Exec Jul 21 2025
Filed Jul 23 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $268K
12,500 sh × $21.40
Exec Jun 20 2025
Filed Jun 24 2025 · 5:30 PM ET More filings →